IP Library Granted Patent US 9,433,614
Granted Patent B2
US 9,433,614 · App. 14/633,985 · Granted Sep 6, 2016

Amides of acetic and propionic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,433,614
App. No.
14/633,985
Granted
Sep 6, 2016
Kind
B2
Abstract

The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.

Claims (65)

1. A method of treating a cognitive impairment in a patient in need thereof, comprising administering to the patient a compound represented by formula (I)

in which

R 1 is 1-azabicyclo[2.2.2]oct-3-yl optionally substituted by (C 1 -C 6 )-alkyl,

A is methylene or ethylene,

R 2 is benzothiophenyl optionally substituted by radicals selected from the group of halogen, formyl, —CO—NR 4 R 5 , —CO—OR 6 , —NR 7 R 8 , —NR 9 —CO—R 10 , cyano, trifluoromethyl, trifluoromethoxy, nitro, optionally hydroxyl-, amino-, —NH—CO—R 11 — or cyano-substituted (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, (C 1 -C 6 )-alkylthio,

in which R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are independently of one another hydrogen, (C 1 -C 6 )-alkyl, phenyl or benzyl,

and

R 3 is hydrogen or (C 1 -C 6 )-alkyl,

or a salt thereof.

2. The method of claim 1 , wherein the cognitive impairment is Alzheimer's disease.

3. The method of claim 2 , wherein

R 1 is 1-azabicyclo[2.2.2]oct-3-yl,

and R 2 and R 3 have the meaning indicated in claim 1 ,

or a salt thereof.

4. The method of claim 3 , wherein

A represents a methylene;

R 2 represents benzotriazolyl optionally substituted by 1 to 3 radicals selected from the group of hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy, nitro, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio, and

R 3 represents hydrogen.

5. The method of claim 3 , where

R 1 is 1-azabicyclo[2.2.2]oct-3-yl,

A is methylene,

R 2 is benzothiophenyl where the rings are optionally substituted by 1 to 3 radicals selected from the group of hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy, nitro, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio,

and

R 3 is hydrogen,

or a salt thereof.

6. The method of claim 3 , where

R 1 is 1-azabicyclo[2.2.2)oct-3-yl,

A is methylene,

R 2 is benzothiophenyl, where the rings are optionally substituted by 1 to 2 radicals selected from the group of hydrogen, fluorine, chlorine, bromine, nitro

and

R 3 is hydrogen,

or a salt thereof.

7. A method of treating a cognitive impairment in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising: i) a compound represented by formula (I)

in which

R 1 is 1-azabicyclo[2.2.2]oct-3-yl optionally substituted by (C 1 -C 6 )-alkyl,

A is methylene or ethylene,

R 2 is benzothiophenyl optionally substituted by radicals selected from the group of halogen, formyl, —CO—NR 4 R 5 , —CO—OR 6 , —NR 7 R 8 , —NR 9 —CO—R 10 , cyano, trifluoromethyl, trifluoromethoxy, nitro, optionally hydroxyl-, amino-, —NH—CO—R 11 — or cyano-substituted (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, (C 1 -C 6 )-alkylthio,

in which R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are independently of one another hydrogen, (C 1 -C 6 )-alkyl, phenyl or benzyl,

and

R 3 is hydrogen or (C 1 -C 6 )-alkyl,

or a salt thereof; and

ii) one or more pharmaceutically acceptable carriers or excipients.

8. The method of claim 7 , wherein the cognitive impairment is Alzheimer's disease.

9. The method of claim 8 , wherein

R 1 is 1-azabicyclo[2.2.2]oct-3-yl,

and R 2 and R 3 have the meaning indicated in claim 7 ,

or a salt thereof.

10. The method of claim 9 , wherein

A represents a methylene;

R 2 represents benzotriazolyl optionally substituted by 1 to 3 radicals selected from the group of hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy, nitro, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio, and

R 3 represents hydrogen.

11. The method of claim 9 , where

R 1 is 1-azabicyclo[2.2.2]oct-3-yl,

A is methylene,

R 2 is benzothiophenyl, where the rings are optionally substituted by 1 to 3 radicals selected from the group of hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy, nitro, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio,

and

R 3 is hydrogen,

or a salt thereof.

12. The method of claim 9 , where

R 1 is 1-azabicyclo[2.2.2)oct-3-yl,

A is methylene,

R 2 is benzothiophenyl, where the rings are optionally substituted by 1 to 2 radicals selected from the group of hydrogen, fluorine, chlorine, bromine, nitro

and

R 3 is hydrogen,

or a salt thereof.

Assignments (4)
MERGER Recorded Sep 6, 2019
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 050301/0352 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2019
From: LUITHLE, JOACHIM; BÖSS, FRANK-GERHARD; ERB, CHRISTINA; SCHNIZLER, KATRIN; FLESSNER, TIMO; VAN KAMPEN, MARJA; METHFESSEL, CHRISTOPH
To: BAYER HEALTHCARE AG
Reel/Frame 048851/0410 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2019
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 048851/0451 →
CHANGE OF NAME Recorded Apr 10, 2019
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 048853/0775 →